$599

Lexicon Q4 ’17 Earnings Update

Lexicon hosted its Q4 ’17 earnings call and provided updates on its T1DM and T2DM sotagliflozin development programs. Interestingly, Lexicon disclosed they plan to file sotagliflozin in T1DM in the US and EU in the coming weeks, which is more specific than previously projected (H1 ’18).

This content is for Read Less members only.
Register
Already a member? Log in here